|
|
Article: Trubion's Series B Brings In $32M For Preclinical SMIPs.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Two-year-old Trubion Pharmaceuticals Inc. raised $32 million in a Series B financing to advance at least two of its small modular immunopharmaceuticals (SMIPs) into Phase I testing.
Lead product TRU-015 should move into the clinic in early 2005 as a treatment for autoimmune and inflammatory diseases. Trubion's second product, TRU-016, would enter a Phase I trial for certain oncology indications after TRU-015.
"The proceeds from this round will be used to advance some of our lead product candidates into and through the initial phases of clinical development," said Peter Thompson, co-founder, president and CEO of Seattle-based ...